Graticule Asia Macro Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Graticule Asia Macro Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-8,700	Closed	-$1.76M	–	182
2015 Q4	$1.76M	Buy	8,700 +6,900	+383%	+$1.23M	0.29%	52
2015 Q3	$262K	Buy	+1,800	New	+$330K	0.03%	83

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Graticule Asia Macro Advisors's BLCM Position: Q1 2016 in Review

Graticule Asia Macro Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2016, closing a stake of 8,700 shares — an estimated $1.76M sold.

Graticule Asia Macro Advisors first reported a position in BLCM in Q3 2015 and held it in 2 quarters. The position peaked at $1.76M in Q4 2015. 78 funds tracked by Wall St. Rank hold BLCM as of Q1 2016.

Graticule Asia Macro Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
Graticule Asia Macro Advisors sold 8,700 Bellicum Pharmaceuticals, Inc. shares in Q1 2016, an estimated $1.76M.
Graticule Asia Macro Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2015 and held it in 2 quarters.
Graticule Asia Macro Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $1.76M in Q4 2015.
78 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2016.

Based on Graticule Asia Macro Advisors's 13F filing for Q1 2016, filed 13 May 2016.